Twenty-four hour growth hormone secretion in patients with panic disorder.
Journal
  Psychoneuroendocrinology.
Citation
  Psychoneuroendocrinology. 30(1):72-9
Publication date
  2005 Jan
Authors
  Abelson JL
Curtis GC
Uhde TW
Investigators
  Thomas W. Uhde
Grant agencies
  National Center for Research Resources
National Institute of Mental Health
Grants
  NCRR M01RR00042
NIMH R01 MH577751
MeSH headings
  Human Growth Hormone
Panic Disorder
MeSH qualifiers
  blood
Abstract
  BACKGROUND: Patients with panic disorder have blunted growth hormone (GH) responses to clonidine, suggesting subsensitivity of post-synaptic alpha(2)-adrenoreceptors, presumably in response to excessive central noradrenergic outflow. However, basal levels of GH release over a full circadian cycle have not been examined in panic. Reduced basal GH release would suggest an overall hypo-active GH system rather than a specific alpha-adrenergic abnormality. METHODS: To determine whether panic patients show reduced basal GH secretion, 20 patients and 12 healthy controls were studied. Blood samples were drawn every 15 min for 24 h and plasma was assayed for GH. Patients were restudied during successful treatment with alprazolam. Groups were compared on overnight and daytime GH secretion and circadian patterns of release. RESULTS: Patients showed normal levels on all measures of GH release. Treatment may have reduced nocturnal GH release slightly, but treated patients still did not differ from controls. The normal predominance of sleep over waking GH secretion was seen in both groups. CONCLUSIONS: Panic patients, in contrast to depressed patients, have normal somatotrophic axis activity when measured in a resting state over a full circadian cycle. GH dysregulation may only be evident in these patients in activation paradigms and has been most consistently demonstrated by challenges with the alpha(2)-noradrenergic agonist, clonidine.